Canton, CT, June 3, 2014 (GLOBE NEWSWIRE) — Kelyniam Global Inc, (OTC: KLYG), a prominent manufacturer of custom cranial implants, today reported that the company generated net income of $71,205 in the first quarter of 2014. Compared with first quarter 2013, net sales increased 23% from $437,415 to $540,286, as a result of increased market...Read More
Kelyniam Global Inc., a manufacturer of custom cranial implants, announces preliminary revenue of $1,857,516 for 2013. This represents an increase of 54% vs. sales of $1,206,227 in 2012. The Kelyniam product fit and quick turnaround has captured the attention of surgeons throughout the United States. The revenue increase reflects the continued rollout in many additional...Read More
Kelyniam Global Inc. (OTC: KLYG) (“the company”) is pleased to announce that it has posted its first ever quarterly profit, for the quarter ending June 30, 2013. Net income for the second quarter was $6,608. Sales in the second quarter were $593,355, up 35% from $438,415 in the first quarter 2013. Year to date sales...Read More
Kelyniam Global, Inc. (OTC: KLYG), today announced that the U.S. Food and Drug Administration (FDA) has granted the company authorization to market Custom Craniofacial Implants made from PEEK OPTIMA material. The approval allows Kelyniam to expand its customer base and pursue ENT doctors, plastic surgeons, Facial/Cranial surgeons, military hospitals and government agencies. Patients with maxiofacial...Read More
Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada magna mollis euismod.
Recent Comments